Adult Dosing

Moderate to severe Alzheimer's dementia

• Initial dose: 5 mg PO qd
• Increase the dose in increments of 5 mg qwk to a maximum of 20 mg/day divided bid
• Max: 20 mg/day (10 mg bid)

Moderate to severe Alzheimer's disease (Namenda XR)

• Initial dose: 7 mg PO qd
• Increase the dose in increments of 7 mg/wk to a maximum of 28 mg qd
• Max: 28 mg PO qd

Note:

• Patients receiving Namenda tabs 10 mg PO bid can switch to Namenda XR Caps 28 mg PO qd; following the last dose of 10 mg Namenda tabs
• Patients receiving Namenda tabs 5 mg PO bid can switch to Namenda XR Caps 14 mg PO qd; following the last dose of 5 mg Namenda tabs

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of moderate to severe Alzheimer's dementia

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment (Based on CrCl)

• Mild-moderate renal impairment: No dose adjustments
• 5-29 mL/min: 5 mg PO bid (Namenda)
• 5-29 mL/min: 14 mg/day (Namenda XR)

Hepatic Dose Adjustment

• Mild-moderate hepatic impairment: No dose adjustments
• Severe impairment: Caution advised

• Conditions that raise urine pH may decrease the urinary elimination of memantine leading to elevated plasma levels of memantine
• Rare events of seizures have been reported with memantine

Cautions: Use cautiously in

• Severe hepatic impairment
• Severe renal impairment
• Renal tubular acidosis
• Hx of urinary tract infection
• History of seizure disorder
• Pregnancy
• Lactation

Pregnancy Category:B

Breastfeeding: Safety unknown. Use with caution.

• CV: Hypertension, hypotension
• CNS: Dizziness, headache, seizures, somnolence
• PSYCHIATRY: Anxiety, depression, aggression
• GI: Constipation, vomiting, diarrhea, abdominal pain
• METABOLIC: Increased weight
• MUSC: Back pain
• GU: Urinary incontinence
• RESP: Coughing, dyspnea
• MISC: Fatigue, pain, influenza

• Anti-Alzheimers's agent: binds to the NMDA receptor-operated cation channels, preventing binding of glutamate, an excitatory neurotransmitter
• Rapidly and well absorbed following oral administration
• Minimally metabolized in liver
• Primarily excreted unchanged in urine (48%)
• Half-life: 60-80 hrs

US Trade Name(s)

• Namenda
• Namenda XR

US Availability

Namenda

• TABS: 5, 10 mg
• SOLN: 2 mg/mL

Namenda XR

• ECAPS: 7, 14, 21, 28 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Ebixa

UK Availability

Ebixa

• TABS: 5, 10, 15, 20 mg
• SOLN: 5 mg/pump

Australian Trade Name(s)

• Ebixa
• Memanxa

Australian Availability

memantine (generic)

• TABS: 10 mg

Ebixa

• TABS: 10, 20 mg
• DROPS: 10 mg/mL

Memanxa

• TABS: 10 mg

[Outline]

Psychiatric

Central Nervous System Agents; Miscellaneous

Neurologic

Central Nervous System Agents; Miscellaneous

Pricing data from www.DrugStore.com in U.S.A.

• Namenda 10 MG TABS [Bottle] (FOREST)
  60 mg = $240.84
  180 mg = $673.93
• Namenda 5 MG TABS [Bottle] (FOREST)
  60 mg = $240
  120 mg = $462.95
• Namenda Titration Pak TABS [Disp Pack] (FOREST)
  49 = $188
  147 = $507.95

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• Namenda (Memantine Hydrochloride 10 MILLIGRAM in 1 TABLET) (Forest Pharmaceuticals, Inc.)
• Namenda (Memantine Hydrochloride 5 MILLIGRAM in 1 TABLET) (Forest Pharmaceuticals, Inc.)
• Namenda 10 MG Oral Tablet (Contract Pharmacy Services-PA)
• Namenda 10 MG Oral Tablet (Forest Pharmaceuticals, Inc.)
• Namenda 10 MG Oral Tablet (Physicians Total Care, Inc.)
• Namenda 5 MG Oral Tablet (Forest Pharmaceuticals, Inc.)
• Namenda 5 MG Oral Tablet (Physicians Total Care, Inc.)